VVV Surges 21% in a Day, Propelled by Strong Performance of Venice-Related Tokens in the Base Ecosystem
BlockBeats News, May 20th, according to GMGN Monitoring, VVV (Venice AI) recorded a 21% increase in the past 24 hours, with its market value peaking at $200 million and currently standing at $195 million, with a price of $17.1 and a daily trading volume of $19.9 million.
Boosted by VVV's strong surge, several related project tokens within the Base ecosystem simultaneously rose in value, including:
DIEM: Market value at $68.4 million, 24-hour increase of 19%. It is the companion token of the Venice AI ecosystem;
POD: Market value at $176 million, rebounding 19% from the daily low. It is the default uncensored AI model provider on the Venice platform;
GITLAWB: Market value at $37.5 million, 24-hour increase of 40%. It is an AI code collaboration platform with deep integration with Venice.
BlockBeats reminds users that on-chain transactions are highly volatile, heavily influenced by market sentiment and speculative concepts; investors should be cautious of the risks involved.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
